Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27743791 | 0.98 | ALOX5 (0.38) | ALOX5THRBTDP1P2RX4CYP2C9 | |
| Bromomethane SCHEMBL208482 | 0.95 | ALOX5 (0.36) | ALOX5THRBTDP1P2RX4CYP2C9 | |
| SCHEMBL10974812 | 0.84 | AKR1B1 (0.43) | ALOX5THRBTDP1P2RX4CYP2C9 | |
| SCHEMBL524258 | 0.84 | KMT2A (0.39) | ALOX5THRBTDP1P2RX4CYP2C9 | |
| Bromomethane SCHEMBL15709779 | 0.82 | ALOX5 (0.35) | ALOX5THRBTDP1P2RX4CYP2C9 | |
| Bromomethane SCHEMBL207850 | 0.81 | KMT2A (0.37) | ALOX5THRBTDP1P2RX4AKR1B1 | |
| Propanol SCHEMBL27803554 | 0.80 | KMT2A (0.36) | ALOX5THRBTDP1P2RX4AKR1B1 | |
| SCHEMBL27681375 | 0.80 | CHRM3 (0.32) | LMNAHRH1MEN1KMT2ACHRM2 | |
| SCHEMBL5285126 | 0.79 | THRB (0.55) | THRBTDP1KMT2AAPEX1 | |
| SCHEMBL4743630 | 0.78 | ALOX5 (0.35) | ALOX5THRBTDP1P2RX4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| EP-2026761-B1 | INHALANT PROPELLANT-FREE AEROSOL FORMULATION | BOEHRINGER INGELHEIM INT (DE) | 2020-04-15 | — | — | EP | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-2011536-A1 | Inhaler | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-01-07 | — | — | EP | disclosed |
| US-7405224-B2 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-07-29 | — | — | US | disclosed |
| CN-101166723-A | New compound for the treatinginflammatory disease | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-04-23 | — | — | CN | disclosed |
| US-20070282276-A1 | PROCESS AND DEVICE FOR DOSING PHARMACEUTICAL AGENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-12-06 | — | — | US | disclosed |
| US-20060134007-A1 | Blister for inhalers | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-22 | — | — | US | disclosed |
| EP-1651224-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | Boehringer Ingelheim International GmbH (DE) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005013994-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-10-30 | — | — | US | disclosed |
| CN-1309655-A | Cyclic compounds useful in treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process | MERCK PATENT GMBH (DE) | 2001-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ALOX5 1906/4885THRB 1526/4885TDP1 4831/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | ALOX5 1323/4885THRB 1837/4885TDP1 2364/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ALOX5 1906/4885THRB 1526/4885TDP1 4831/4885 |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F11, NR3C2 | ALOX5 2833/4885THRB 3210/4885TDP1 2982/4885 |
| US-12209094-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ALOX5 1906/4885THRB 1526/4885TDP1 4831/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | ALOX5 1020/4885THRB 804/4885TDP1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.